ACH at a glance
ACCENDRA HEALTH INC/VA/ (ACH, SEC CIK 75252) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ACCENDRA HEALTH INC/VA/ (ACH) reported revenue of $2.8 billion (down 74.2% from FY2024) and a net loss of $1.1 billion. Diluted EPS was -$14.31.
- The most recent insider open-market sale reported on Form 4 was by Bernocchi Perry A on November 16, 2026 of 33,161 shares at $0.12 per share.
- In the last 90 days, ACH insiders reported 0 open-market purchases ($0) and 1 open-market sale ($4K) on Form 4, a net sale of $4K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.8B
- −74.2% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$4K
- Latest 8-K
- Nov 18, 2026
- Item 7.01 · Item 3.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Net revenue $601.8M, down 13.7% YoY from $697.3M, driven by commercial Payor contract termination
- Cost margin 43.4% vs 46.2% YoY, with cost of net revenue 56.6% vs 53.8%
- Best segment: Ostomy revenue $55.2M, up 3.7%; worst: Sleep therapy $144.5M, down 22.2%
- Cash $26.6M vs $282.0M at December 31, 2025; operating cash flow $(93.5)M
- Free cash flow $(5.8)M vs $29.2M YoY; management cites value creation plan and continued sleep and respiratory growth needs
Risk Factors
- NYSE price compliance risk: October 6, 2026 notice after 30-day average below $1, requiring cure within six months
- NYSE capitalization compliance risk: October 27, 2026 notice for market capitalization and equity below $50 million
- Delisting risk: reverse split proposal, targeted at 1-for-20 to 1-for-30, requires shareholder approval
- Management transition risk: executive departures could cause operational inefficiencies and increased turnover
- No other material changes through September 30, 2026 beyond identified NYSE and leadership risks
AI summary of the ACH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Accendra Health disclosed a press release addressing Nasdaq’s delisting determination
- Delisting risk threatens continued exchange trading, liquidity, and investor access to ACH shares
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- NYSE suspended trading and began delisting proceedings for ACH due to abnormally low share-price levels
- Company will not appeal, eliminating the primary path to retain its NYSE listing
Item EX-99.1: Item EX-99.1
- NYSE suspended ACH trading immediately and began delisting proceedings under Rule 802.01D for abnormally low share prices
- Common stock moved to OTCQB on November 17, 2026 under ticker ACCH, reducing exchange-market visibility and liquidity
Item 2.02: Results of Operations and Financial Condition
- Q3 and nine-month fiscal 2026 results released for periods ended September 30, 2026
- Press release issued November 5, 2026, containing the company’s financial results
Item 7.01: Regulation FD Disclosure
- Earnings presentation posted November 5, 2026 on Accendra Health’s Investor Relations website
- Presentation provides supplemental investor information and is included as Exhibit 99.2
Item EX-99.2: Item EX-99.2
- Q3 2026 continuing-operations revenue $602M, down from $697M after large commercial payor loss and cost pressures
- Adjusted EBITDA $48M, down from $92M, reflecting volume declines, manufacturer cost increases and collection-rate pressure
Item EX-99.1: Item EX-99.1
- Q3 revenue fell to $601.8M from $697.3M, while adjusted EBITDA dropped to $47.8M from $92.2M
- Continuing-operations adjusted EPS swung to a $0.23 loss from $0.25 income
Item 5.02: Departure/Appointment of Directors or Principal Officers
- COO Perry A. Bernocchi transitioning to Strategic Advisor through December 31, 2026
- Executive officer departure creates near-term leadership transition risk at operations
AI summaries of ACH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ACH
Don't miss the next ACH filing
- Alerts as it files. A push when ACH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ACH, by share count.
- Ask anything. An AI agent that reads every ACH filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Bernocchi Perry A | Sell | Nov 16, 2026 | 33,161 | $0.12 |
| Gardner-Smith Kenneth | A | Oct 5, 2026 | 283,554 | - |
| Leon Jonathan A | F | Sep 23, 2026 | 4,265 | $0.85 |
| Galloway Heath H | F | May 18, 2026 | 1,822 | $2.91 |
| Galloway Heath H | F | May 15, 2026 | 966 | $3.04 |
| Gardner-Smith Kenneth | A | May 14, 2026 | 31,191 | - |
| Leon Jonathan A | F | Mar 20, 2026 | 11,286 | $2.03 |
| Bernocchi Perry A | F | Mar 20, 2026 | 20,841 | $2.03 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $10.7B | $2.8B |
| Gross Profit | - | $2.2B | - |
| Operating Income | - | -$207.8M | $27.5M |
| Net Income | - | -$362.7M | -$1.1B |
| Gross Margin | - | 20.7% | - |
| Op. Margin | - | -1.9% | 1.0% |
| Net Margin | - | -3.4% | -39.8% |
| Balance Sheet | |||
| Total Assets | $5.1B | $4.7B | $2.5B |
| Equity | $924.2M | $565.2M | -$461.0M |
| ROE | - | -64.2% | 238.8% |
| Per Share | |||
| EPS | - | $-4.73 | $-14.31 |
| Cash Flow | |||
| Operating CF | - | $161.5M | -$101.8M |
| CapEx | $190.9M | $210.9M | $191.0M |
Source: XBRL data in ACCENDRA HEALTH INC/VA/ (ACH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
ACH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 18, 2026 | - | Analysis | - |
| 4 | Nov 17, 2026 | - | - | - |
| 10-Q | Nov 6, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 8-K | Oct 30, 2026 | - | Analysis | - |
| 8-K | Oct 9, 2026 | - | Analysis | - |
| 4 | Oct 6, 2026 | - | - | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 4 | Sep 24, 2026 | - | - | - |
| 8-K | Sep 17, 2026 | - | Analysis | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 8-K | Jun 25, 2026 | - | - | - |
| 8-K | Jun 15, 2026 | - | - | - |
| 8-K | May 22, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 8-K | May 15, 2026 | - | - | |
| 8-K | May 11, 2026 | - | - |
Related Health Care companies
- HSIC · Henry ScheinWholesale-Medical, Dental & Hospital Equipment & Supplies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
ACH SEC filings: frequently asked questions
Are ACH insiders buying or selling?
In the last 90 days, ACCENDRA HEALTH INC/VA/ (ACH) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $4,046 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
What was ACH's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ACCENDRA HEALTH INC/VA/ (ACH) reported revenue of $2.8 billion (down 74.2% from FY2024) and a net loss of $1.1 billion. Diluted EPS was -$14.31. The figures come from the XBRL data in the 10-K.
What did ACH report in its latest 8-K?
ACCENDRA HEALTH INC/VA/ (ACH) filed an 8-K on November 18, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule). Accendra Health disclosed a press release addressing Nasdaq’s delisting determination.
What are the latest ACH SEC filings?
ACCENDRA HEALTH INC/VA/ (ACH) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on November 17, 2026.
What is ACH's SEC CIK number?
ACCENDRA HEALTH INC/VA/ (ACH)'s SEC Central Index Key (CIK) is 75252. EDGAR lists every ACH filing under that number.
Ask anything about ACH
The research agent reads ACH's filings, financials, insider trades and 13F holders, then answers with sources.